NBDF/ LinkedIn
Aug 31, 2025, 07:31
Avatrombopag Shows Promise for Pediatric Immune Thrombocytopenia in Late-Stage Global Trial: NBDF
National Bleeding Disorders Foundation shared on LinkedIn:
“Promising news for children and adolescents living with immune thrombocytopenia (ITP). A late-stage global trial shows avatrombopag, an oral treatment already approved for adults, can significantly improve platelet counts and reduce bleeding symptoms in pediatric patients, offering a potential new treatment option for an underserved population.
Learn more about the study results and what they could mean for pediatric ITP care in The Lancet Haematology.”
Stay updated with Hemostasis Today.
-
Sep 13, 2026, 14:52Omar Al Hammadi: Integrating Diabetes and Dyslipidemia in Modern Clinical Care
-
Sep 13, 2026, 14:37Mohammad Zamrood Khan: Hereditary Spherocytosis and Protein C/S Deficiency Case Report Submitted
-
Sep 13, 2026, 14:33Heghine Khachatryan: A Resource-Adapted Approach to Hemophilia Joint Care
-
Sep 13, 2026, 14:23Simon Fletcher: The Unmet Burden of Factor VII Deficiency
-
Sep 13, 2026, 14:10Azusa Nagao: The Evolving Burden of Haemophilia Prophylaxis
-
Sep 13, 2026, 13:50Priya Sriskandarajah: The Challenge of Thrombotic Risk in Myeloproliferative Neoplasms
-
Sep 13, 2026, 12:31Vishakha K. Kumar: ISTH Opens Public Comment Period on New Guidance
-
Sep 13, 2026, 12:13Tahsin Ara Mim: Takayasu’s Arteritis Case Report Secures 2nd Runner-Up
-
Sep 13, 2026, 11:26Tareq Abadl: When Good Samples Give Bad Numbers – Spotting EDTA Contamination in the Lab